Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CB-012,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Caribou Biosciences Presents Data on CB-012 CAR-T Cell Therapy at AACR Meeting
Details : CB-012 is an allogeneic anti-CLL-1 CAR-T cell therapy that exhibits specific and potent cytotoxicity. It is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia.
Product Name : CB-012
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 03, 2024
Lead Product(s) : CB-012,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : BofA Securities
Deal Size : $125.0 million
Deal Type : Public Offering
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
Details : The proceeds will fund manufacturing and clinical development of company's CB-010 and CB-011 product candidates; IND-enabling activities, manufacturing, and clinical development of its CB-012 product candidate and preclinical development of its CB-020 pr...
Product Name : CB-010
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : BofA Securities
Deal Size : $125.0 million
Deal Type : Public Offering
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CB-010 is the lead product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
Product Name : CB-010
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
Details : Caribou will use the net proceeds to advance CB-011, an immune cloaked allogeneic CAR-T cell therapy currently being evaluated in the CaMMouflage Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma (r/r MM).
Product Name : CB-011
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 07, 2023
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
Details : Caribou will use the proceeds of this investment to advance CB-011, an immune cloaked allogeneic CAR-T cell therapy currently being evaluated in the CaMMouflage Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma (r/r MM).
Product Name : CB-011
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 07, 2023
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Caribou Biosciences Reports Data From Non-hodgkin Lymphoma Therapy Trial
Details : CB-010 is the lead product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1 trial.
Product Name : CB-010
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results demonstrated, 100% overall response rate (ORR) and 80% complete response rate (CR) in cohort 1 (n=5 evaluable) from its ANTLER Phase 1 trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
Product Name : CB-010
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CB-010 is the lead product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in patients with r/r B-NHL in the ongoing ANTLER Phase 1 trial.
Product Name : CB-010
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CB-010 is an allogeneic anti-CD19 CAR-T cell therapy engineered using Cas9 CRISPR hybrid RNA-DNA (chRDNA) technology to insert a CD19-specific CAR into the TRAC gene and knock out PD-1 to boost the persistence of antitumor activity.
Product Name : CB-010
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : CB-010,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $340.0 million
Deal Type : Collaboration
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Details : Under the multi-year agreement, AbbVie will utilize Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVi...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $40.0 million
October 02, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $340.0 million
Deal Type : Collaboration